{
    "Trade/Device Name(s)": [
        "Tissue of Origin Test Kit-FFPE",
        "Cancer Genetics Tissue of Origin Test Kit-FFPE"
    ],
    "Submitter Information": "Cancer Genetics, Inc.",
    "510(k) Number": "K173839",
    "Predicate Device Reference 510(k) Number(s)": [
        "K120489",
        "K092967"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OIW"
    ],
    "Summary Letter Date": "December 15, 2017",
    "Summary Letter Received Date": "December 18, 2017",
    "Submission Date": "December 15, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.3100"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system"
    ],
    "Analyte Class(es)": [
        "cancer molecular"
    ],
    "Analyte(s)": [
        "RNA expression patterns"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded (FFPE) tumor tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Affymetrix GeneChip Fluidics Station FS450Dx v2",
        "Affymetrix GeneChip Scanner GCS3000Dx",
        "Affymetrix Workstation with GeneChip Operating System (GCOS)"
    ],
    "Method(s)/Technology(ies)": [
        "Microarray",
        "Gene expression analysis"
    ],
    "Methodologies": [
        "Gene expression profiling"
    ],
    "Submission Type(s)": [
        "Kit",
        "Reagent",
        "Software",
        "Microarray",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Cancer Genetics Tissue of Origin Test Kit-FFPE, a microarray-based gene expression profiling system for comparing RNA expression patterns in FFPE tumor samples to a reference database of 15 tumor types.",
    "Indications for Use Summary": "Measures degree of similarity between a patient's FFPE tumor RNA expression patterns and a database of fifteen tumor types; results to be evaluated by a qualified physician in the context of clinical history and other diagnostic test results.",
    "fda_folder": "Toxicology"
}